Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company
focused on the development of novel, proprietary therapeutics based on
hypoxia-inducible factor (HIF) biology and the commercialization of
these products for patients with kidney disease, today announced that
the first patient has been dosed in a Phase 2 clinical study of AKB-6548
in patients with anemia related to chronic kidney disease (CKD) who are
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.